Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.

CONCLUSION: This updated network meta-analysis confirms that clopidogrel significantly decreases the risk of major adverse cardiovascular events compared with aspirin, without increasing bleeding risk. Clopidogrel should remain a mainstay of PAD treatment, at least in patients at higher bleeding risk. PMID: 32819249 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32819249?dopt=Abstract

Source: Current Vascular Pharmacology - August 19, 2020 Category: Drugs & Pharmacology Authors: De Carlo M, Di Minno G, Sayre T, Fazeli MS, Siliman G, Cimminiello C Tags: Curr Vasc Pharmacol Source Type: research